Why the first penguin of pay for delay has not come in Japan-Anatomy of the Japanese Paradox


In this session Takanori Abe will explore the reasons why reverse payment cases are so scant in Japan.  With their low invalidation rate of substance patents, and the stable supply obligation after the launch of generic drugs, the system in Japan makes reverse payments very difficult.  On the other hand, the reasons why actual reverse payments cases have not arisen in Japan cannot be solely explained by the systems in place.  The attitude of Japanese companies’ towards regulatory authorities may be a significant factor.